Van de Velde N - Search Results

1

Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.

Brisson M, Laprise JF, Drolet M, Van de Velde N, Franco EL, Kliewer EV, Ogilvie G, Deeks SL, Boily MC. Brisson M, et al. Among authors: van de velde n. Vaccine. 2013 Aug 20;31(37):3863-71. doi: 10.1016/j.vaccine.2013.06.064. Epub 2013 Jul 3. Vaccine. 2013. PMID: 23830974

2

Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty.

Van de Velde N, Brisson M, Boily MC. Van de Velde N, et al. Am J Epidemiol. 2007 Apr 1;165(7):762-75. doi: 10.1093/aje/kwk059. Epub 2007 Feb 1. Am J Epidemiol. 2007. PMID: 17276976

3

The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada.

Brisson M, Van de Velde N, De Wals P, Boily MC. Brisson M, et al. Among authors: van de velde n, de wals p. Vaccine. 2007 Jul 20;25(29):5399-408. doi: 10.1016/j.vaccine.2007.04.086. Epub 2007 May 22. Vaccine. 2007. PMID: 17561316

4

Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection.

Brisson M, Van de Velde N, De Wals P, Boily MC. Brisson M, et al. Among authors: van de velde n, de wals p. CMAJ. 2007 Aug 28;177(5):464-8. doi: 10.1503/cmaj.061709. Epub 2007 Aug 20. CMAJ. 2007. PMID: 17709404 Free PMC article.

5

Economic evaluation of human papillomavirus vaccination in developed countries.

Brisson M, Van de Velde N, Boily MC. Brisson M, et al. Among authors: van de velde n. Public Health Genomics. 2009;12(5-6):343-51. doi: 10.1159/000214924. Epub 2009 Aug 11. Public Health Genomics. 2009. PMID: 19684446 Review.

6

Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis.

Van de Velde N, Brisson M, Boily MC. Van de Velde N, et al. Vaccine. 2010 Jul 26;28(33):5473-84. doi: 10.1016/j.vaccine.2010.05.056. Epub 2010 Jun 2. Vaccine. 2010. PMID: 20573580

7

Different population-level vaccination effectiveness for HPV types 16, 18, 6 and 11.

Brisson M, Van de Velde N, Boily MC. Brisson M, et al. Among authors: van de velde n. Sex Transm Infect. 2011 Feb;87(1):41-3. doi: 10.1136/sti.2010.044412. Epub 2010 Oct 5. Sex Transm Infect. 2011. PMID: 20924049

8

Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity.

Brisson M, van de Velde N, Franco EL, Drolet M, Boily MC. Brisson M, et al. Among authors: van de velde n. J Infect Dis. 2011 Aug 1;204(3):372-6. doi: 10.1093/infdis/jir285. J Infect Dis. 2011. PMID: 21742835

9

Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.

Van de Velde N, Boily MC, Drolet M, Franco EL, Mayrand MH, Kliewer EV, Coutlée F, Laprise JF, Malagón T, Brisson M. Van de Velde N, et al. J Natl Cancer Inst. 2012 Nov 21;104(22):1712-23. doi: 10.1093/jnci/djs395. Epub 2012 Oct 27. J Natl Cancer Inst. 2012. PMID: 23104323

10

The impact of differential uptake of HPV vaccine by sexual risks on health inequalities: a model-based analysis.

Malagón T, Joumier V, Boily MC, Van de Velde N, Drolet M, Brisson M. Malagón T, et al. Among authors: van de velde n. Vaccine. 2013 Mar 25;31(13):1740-7. doi: 10.1016/j.vaccine.2013.01.026. Epub 2013 Feb 4. Vaccine. 2013. PMID: 23384753

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

100 results

Search Page

Filters